Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis
Prospective Multicentre Randomized Double-blind Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis
Centre Hospitalier Universitaire, Amiens
448 participants
Jan 1, 2019
INTERVENTIONAL
Conditions
Summary
The incidence of intra-abdominal candidiasis is increasing, and it is now the leading indication for antifungal therapy, ahead of candidemia. Prospective randomized trials of antifungal therapy have almost exclusively concerned patients with candidemia and did not include patients with intra-abdominal infections. The aim of this study is to demonstrate that caspofungin antifungal therapy for intra-abdominal candidiasis in ICU patients is associated with lower failure rate compared to placebo.
Eligibility
Inclusion Criteria6
- Age ≥ 18 years old
- Covered by national health insurance
- Admitted to ICU after surgery for intra-abdominal infection :
- With suspected intra-abdominal candidiasis defined by a Peritonitis score ≥ 3(1)
- Or with documented intra-abdominal candidiasis defined by positive direct examination or positive culture of peritoneal fluid collected intraoperatively.
- With written and signed informed consent
Exclusion Criteria9
- Allergy to caspofungin
- Life expectancy ≤ 48h
- Expected withdrawal of treatment
- Radiological drainage without surgery
- Severe hepatic impairment (Child-Pugh C score)
- Pregnant or lactating women
- Immunodepression (treatment including long-term corticosteroids, anti-TNF or disease including transplant patients)
- Infected acute pancreatitis
- Ascites fluid infection
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
caspofungin
placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03580733